Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) represents a completely new ...

Please provide your email address to receive an email when new articles are posted on . A 0.5 mg dose of colchicine has been approved for use in high-risk patients who have inflammatory risk. The dose ...

NEW YORK (Reuters Health) - The gout drug colchicine is safe for women to take during pregnancy, report researchers from Israel. In addition to the debilitating joint disorder gout, the ...

The FDA approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such ...

Depending on one’s perspective, the anti-inflammatory colchicine is either an unsung and underprescribed drug for patients with cardiovascular disease, or it’s an agent with limited clinical benefit ...

The presence of an operational classification of drug interactions (ORCA) class 3 or 4 drug-drug interactions (DDIs) did not increase the risk for colchicine-related gastrointestinal adverse events or ...